Barclays raised the firm’s price target on Revolution Medicines (RVMD) to $72 from $60 and keeps an Overweight rating on the shares post the Q3 report. The firm cites the “encouraging” pancreatic data for the target increase.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines price target raised to $64 from $62 at H.C. Wainwright
- Revolution Medicines Reports Q3 2024 Results and Progress
- Revolution Medicines reports Q3 EPS (94c), consensus (89c)
- Revolution Medicines price target raised to $62 from $56 at H.C. Wainwright
- Revolution Medicines price target raised to $82 from $72 at Guggenheim